Stopping Antibiotics After 3 Days for the Treatment of High-risk FEbrile Neutropenia

Recruiting Phase 4 Interventional Study
Neutropenia, Febrile
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
16 and older
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Supportive Care
Participants needed
410 (estimated)
Sponsor
Universitaire Ziekenhuizen KU Leuven · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this clinical trial is to compare a short course of antibiotics in patients in whom no bacterial infection is found with the current "golden standard": long-term antibiotic treatment in adult hematology patients who develop neutropenic fever. The main question it aims to answer is: whether the short-term treatment is equally safe for patients, hence the name 'SAFE study'. Participant…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures; * Age older than 16 years; * Intensive therapy is started within three days before randomization for one of the following haema…
Contacts

Robina Aerts, MD

+32 16 34 48 77

robina.aerts@kuleuven.be

CONTACT

Johan Maertens, MD, PhD

+32 16 34 66 70

johan.maertens@uzleuven.be

CONTACT